These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39278459)

  • 1. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: Prediction of in vivo drug-drug interactions.
    Xiao S; Yin H; Lv X; Wang Z; Jiang L; Xia Y; Liu Y
    Chem Biol Interact; 2024 Nov; 403():111246. PubMed ID: 39278459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases.
    Lv X; Wang Z; Wang Z; Yin H; Xia Y; Jiang L; Liu Y
    Chem Biol Interact; 2023 Aug; 381():110574. PubMed ID: 37263554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib Carries the Risk of Drug-Drug Interactions
    Wang Z; Jiang L; Wang X; Yin H; Wang Z; Lv X; Liu Y
    Curr Drug Metab; 2022; 23(11):912-919. PubMed ID: 36306450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions.
    Lv X; Wang Z; Wang Z; Yin H; Xia Y; Jiang L; Liu Y
    Toxicol Appl Pharmacol; 2023 May; 466():116490. PubMed ID: 36963523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast.
    Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M
    Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.
    Wang Z; Wang X; Wang Z; Jia Y; Feng Y; Jiang L; Xia Y; Cao J; Liu Y
    Toxicol Lett; 2021 Sep; 348():10-17. PubMed ID: 34044055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions.
    Lee SJ; Park JB; Kim D; Bae SH; Chin YW; Oh E; Bae SK
    Toxicol Lett; 2015 Jan; 232(2):458-65. PubMed ID: 25448279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions.
    Yin H; Wang Z; Lv X; Wang Z; Wang Y; Fan W; Li S; Jiang L; Cao J; Liu Y
    Chem Biol Interact; 2024 May; 395():111023. PubMed ID: 38677539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions.
    Yin H; Wang Z; Wang X; Lv X; Fan X; Yan M; Jia Y; Jiang L; Cao J; Liu Y
    Biomed Chromatogr; 2021 Nov; 35(11):e5205. PubMed ID: 34192355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19.
    Hou L; Zhao Y; Zhao S; Zhang X; Yao X; Yang J; Wang Z; Chan ECY; Liu S
    Chem Biol Interact; 2024 Jan; 387():110811. PubMed ID: 37993078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3 and 1A8.
    Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2006; 31(4):299-309. PubMed ID: 17315542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Inhibition of Human UDP-Glucuronosyl-Transferase (UGT) Isoforms by Astaxanthin, β-Cryptoxanthin, Canthaxanthin, Lutein, and Zeaxanthin: Prediction of in Vivo Dietary Supplement-Drug Interactions.
    Zheng YF; Min JS; Kim D; Park JB; Choi SW; Lee ES; Na K; Bae SK
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27529203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avapritinib Carries the Risk of Drug Interaction
    Lv X; Wang Z; Wang Z; Yin H; Xia Y; Jiang L; Liu Y
    Curr Drug Metab; 2024; 25(3):197-204. PubMed ID: 38803186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
    Liu Y; Ramírez J; House L; Ratain MJ
    Drug Metab Dispos; 2010 Jan; 38(1):32-9. PubMed ID: 19850672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.
    Zhang N; Liu Y; Jeong H
    Sci Rep; 2015 Dec; 5():17778. PubMed ID: 26642944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro glucuronidation of the primary metabolite of 10-chloromethyl-11-demethyl-12-oxo-calanolide A by human liver microsomes and its interactions with UDP-glucuronosyltransferase substrates.
    Liu X; Sheng L; Zhao M; Mi J; Liu Z; Li Y
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):89-96. PubMed ID: 25760535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases.
    Ai L; Zhu L; Yang L; Ge G; Cao Y; Liu Y; Fang Z; Zhang Y
    Xenobiotica; 2014 Apr; 44(4):320-5. PubMed ID: 24066723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
    Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
    Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs).
    Du Z; Wang G; Cao YF; Hu CM; Yang K; Liu YZ; Zhang CZ; Zhang WH; Zhu ZT; Sun HZ; Sun XY; Hong M; Fang ZZ
    Xenobiotica; 2018 May; 48(5):452-458. PubMed ID: 28548030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
    Korprasertthaworn P; Chau N; Nair PC; Rowland A; Miners JO
    Biochem Pharmacol; 2019 Nov; 169():113616. PubMed ID: 31445021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.